Get started
Author

Svetlana Samarina

Observed names: S V Samarina, S. Samarina, S. V. Samarina, Svetlana V. Samarina, Svetlana Valerevna Samarina, Svetlana Valer’evna Samarina, Самарина Светлана Валерьевна
ORCID: 0000-0001-8639-719X
Observed ORCID: 0000-0001-8639-719X
OpenAlex ID: A5017073753
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial
2024 · Elias Jabbour, Vivian G. Oehler, et al. · JAMA Oncology · 45
Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
2023 · Elias Jabbour, Hagop M. Kantarjian, et al. · Blood · 13
The role of рАКТ1 expression in diffuse large B-cell lymphoma
2021 · E. V. Vaneeva, V. A. Rosin, et al. · Bulletin of Siberian Medicine · 5
PDF
Clinical and Hematological Predictors of Response to First-Line Therapy in Patients with Diffuse Large B-Cell Lymphoma
2019 · Svetlana Valer’evna Samarina, E. L. Nazarova, et al. · Clinical oncohematology · 4
PDF
Sociomedical Profile and Quality of Life of Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Pathogenetic Therapy
2025 · T. I. Ionova, A. D. Kulagin, et al. · Clinical oncohematology · 2
PDF
CML-400 Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2024 · Elias Jabbour, Vivian G. Oehler, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Venetoclax after Progression on Ibrutinib: Results of a Russian Multicenter Study
2023 · Maria Kislova, Olga Kalashnikova, et al. · Blood · 2
Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma
2019 · S. V. Samarina, A. S. Luchinin, et al. · Clinical oncohematology · 2
PDF
Results of a Double-Blind Prospective Comparative Randomized Phase 3 Clinical Trial of the Efficacy and Safety of BCD-264 and Darzalex as Monotherapy for Relapsed/Refractory Multiple Myeloma (BCD-264-2/DARVIVA)
2026 · T. V. Shelekhova, J. Kumar, et al. · Clinical oncohematology · 1
PDF
Pola-R-CHP in previously untreated diffuse large B-cell lymphoma: Real-world data in Russia
2025 · Gayane Tumyan, Anastasia Semenova, et al. · Blood · 1
Real-world outcomes of glofitamab therapy in CAR-T naive patients with relapsed/refractory B-cell lymphoma
2025 · Liudmila Fedorova, Nataliia Mikhailova, et al. · Blood · 1
PDF
Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
2024 · Elias Jabbour, Omer Jamy, et al. · Blood · 1
PDF
Efficacy and Safety of Pola-BR Combination in Relapsed/Refractory Aggressive В-Cell Non-Hodgkin’s Lymphomas: A Russian Multi-Center Study
2022 · Olesya Gennadevna Smykova, A. A. Semenova, et al. · Clinical oncohematology · 1
Obinutuzumab-Based Regimens in the First-Line Therapy for Follicular Lymphoma: Data from Real-World Clinical Practice in 41 Medical Institutions
2026 · Lali Galimovna Babicheva, G. S. Tumyan, et al. · Clinical oncohematology
PDF
Real-world management of patients with paroxysmal nocturnal hemoglobinuria in Russia: outcomes of the multicenter retrospective RADAR-PNH study
2026 · B. A. Bakirov, G. P. Dimov, et al. · Oncohematology
PDF
Real-world outcomes of glofitamab therapy in CAR-T–naïve patients with relapsed/refractory large B-cell lymphoma
2026 · Liudmila Fedorova, Natalia Mikhailova, et al. · Blood Immunology & Cellular Therapy
Pola-R-CHP Regimen as First-Line Therapy for Diffuse Large B-Cell Lymphoma: A Retrospective Study of Real-World Clinical Practice
2026 · Anastasiya Aleksandrovna Semenova, G. S. Tumyan, et al. · Clinical oncohematology
PDF
Efficacy and Safety of Glofitamab Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A United Russian Experience Based on the Compassionate Use Program
2026 · Liudmila Valerevna Fedorova, N. B. Mikhailova, et al. · Clinical oncohematology
PDF
Prognostic significance of AIF expression in diffuse large B-cell lymphoma
2025 · Vitaly A. Rosin, Elena V. Vaneeva, et al. · Terapevticheskii arkhiv
Bruton Tyrosine Kinase Inhibitors for the Treatment of Relapsed Mantle Cell Lymphoma Involving CNS: Two Case Reports and Literature Review
2025 · Evgenii Olegovich Kunevich, N. N. Nemstsveridze, et al. · Clinical oncohematology
PDF
Olverembatinib (HQP1351) Overcomes Ponatinib and/or Asciminib Resistance in Patients With Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
2024 · Elias Jabbour, Vivian G. Oehler, et al. · Clinical Lymphoma Myeloma & Leukemia
Prognostic value of p14ARF expression in diffuse large B cell lymphoma
2024 · М. V. Sarpova, Е. V. Vaneeva, et al. · Сибирский научный медицинский журнал
PDF
Association of CDKN2A/B deletions with survival of patients with diffuse large B-cell lymphoma
2024 · M. V. Sarpova, E. V. Tregubova, et al. · Bulletin of Siberian Medicine
PDF
Pb2404: Association of P14arf Expression With the Risk of Progression and Death in Diffuse Large B-cell Lymphoma
2023 · Maria Sarpova, Elena Vaneeva, et al. · HemaSphere
Pb2403: the Frequency of L265p Mutation in Myd88 Gene at Diffuse Large B-cell Lymphoma
2023 · Anastasiya Dubrovina, Ekaterina Tregubova, et al. · HemaSphere
Works count: 39
Citation count: 80
H-index: 4
I10-index: 2
Year
Topic
Type